U.S. Food and Drug Administration Approves Crizotinib (Xalkori) for Pediatric ALCL
U.S. Food and Drug Administration (FDA) approved the first biomarker-driven therapy for pediatric ALCL.
News
Ask the Doctor: What is the role of checkpoint inhibitors for the treatment of Hodgkin lymphoma (HL)?
Checkpoint inhibitors are a new class of drugs used by the immune system to determine whether or not to launch an immune response. By activating these checkpoints, cancers evade detection by the immune system as something that is bad for…
Managing Stress Amid a Pandemic
A lymphoma diagnosis can be challenging to cope with at any time, but the current pandemic has only increased stress, anxiety, and depression for many lymphoma patients. While at times this can all be overwhelming, there are many ways to…
Ask the Doctor: How can biomarker testing help DLBCL patients?
The emergence of biomarking testing has provided new insights into the molecular and genetic underpinnings of many types of cancer as well as differences in an individual patient’s cancer at the molecular level. These differences, or alterations (also known as…
Ask the Doctor: What do lymphoma patients need to know about the COVID-19 vaccines?
On December 11 and 18, 2020 the U.S. Food and Drug Administration (FDA) issued two COVID-19 vaccines, Pfzier BioNTech and Moderna, with emergency use authorization (EUA). LRF Scientific Advisory Board Member, John Leonard, MD (NewYork-Presbyterian Hospital, Weill Cornell Medicine) answered…
LRF Showcases Impressive Number of Researchers at 2020 American Society of Hematology Annual Meeting
LRF Scientific Advisory Board Members joined by current and former grantees at the 62nd ASH Annual Meeting & Exposition
Ask the Doctor: Are there clinical trials showing that CAR-T is an effective treatment for chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)?
In May 2020, lymphoma-expert, Raghuveer Ranganthan, MD (Univerity of Southern California) hosted the Lymphoma Research Foundation’s Update on CAR T-Cell Therapy in Diffuse Large B-cell Lymphoma Webinar. Due to the interest surrounding CAR T-cell therapy to treat various types of…
Ask the Doctor: How can patients access innovative drug treatments when insurance won’t cover the cost?
During the Lymphoma Research Foundation’s Denver Ask the Doctor About Lymphoma Program, lymphoma-expert and program host, John M. Burke, MD (Rocky Mountain Cancer Center), provided the following answer to this question: How can patients access innovative drug treatments when insurance…
Trading Places: A Father and Daughter’s Journey with Lymphoma
A father and daughter’s story as both lymphoma survivors and each other’s caregivers, and their mission to empower themselves through education and connect with others at Lymphoma Research Foundation (LRF)’s North American Educational Forum on Lymphoma.
Meet the Newly Elected LRF Scientific Advisory Board Members
The Lymphoma Research Foundation (LRF) welcomed three new members to its elite Scientific Advisory Board (SAB) on July 1. The new members represent distinct specialties that will contribute to the global impact of the Foundation.